haloperidol has been researched along with Abdominal Pain in 6 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 9.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 8.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| " Patients must have had ≥ 2 ED encounters for abdominal pain, one in which they received conventional therapy with opioids (C-encounter), and the other in which they received haloperidol (H-encounter)." | 8.02 | Study of Haloperidol for Abdominal Pain in the Emergency Department (SHAPE). ( Fertel, BS; Harbert, B; Knudsen-Lachendro, K; Stith, K; Vicarel, LA, 2021) |
| "Haloperidol was not associated with decreased i." | 5.56 | Does administration of haloperidol or ketorolac decrease opioid administration for abdominal pain patients? A retrospective study. ( Bebarta, VS; Heard, K; Hoppe, JA; Monte, AA, 2020) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 5.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 5.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 4.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| " Patients must have had ≥ 2 ED encounters for abdominal pain, one in which they received conventional therapy with opioids (C-encounter), and the other in which they received haloperidol (H-encounter)." | 4.02 | Study of Haloperidol for Abdominal Pain in the Emergency Department (SHAPE). ( Fertel, BS; Harbert, B; Knudsen-Lachendro, K; Stith, K; Vicarel, LA, 2021) |
| "Haloperidol was not associated with decreased i." | 1.56 | Does administration of haloperidol or ketorolac decrease opioid administration for abdominal pain patients? A retrospective study. ( Bebarta, VS; Heard, K; Hoppe, JA; Monte, AA, 2020) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 1.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shahsavari, D | 1 |
| Reznick-Lipina, K | 1 |
| Malik, Z | 1 |
| Weiner, M | 1 |
| Jehangir, A | 1 |
| Repanshek, ZD | 1 |
| Parkman, HP | 1 |
| Knudsen-Lachendro, K | 1 |
| Stith, K | 1 |
| Vicarel, LA | 1 |
| Harbert, B | 1 |
| Fertel, BS | 1 |
| Ramirez, R | 1 |
| Stalcup, P | 1 |
| Croft, B | 1 |
| Darracq, MA | 1 |
| Roldan, CJ | 1 |
| Chambers, KA | 1 |
| Paniagua, L | 1 |
| Patel, S | 1 |
| Cardenas-Turanzas, M | 1 |
| Chathampally, Y | 1 |
| Heard, K | 1 |
| Bebarta, VS | 1 |
| Hoppe, JA | 1 |
| Monte, AA | 1 |
| Hickey, JL | 1 |
| Witsil, JC | 1 |
| Mycyk, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Haloperidol vs Conventional Therapy for Gastroparesis[NCT02057549] | Phase 4 | 36 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to PI left institution) | ||
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The time frame starts from the moment of receiving the study drug to the time when the decision for final disposition is made. Usually after symptoms are controlled, patients are given a PO challenge (food or drink) in order to establish if they are OK to go home. If symptoms return, additional medications are given, the treatment is consider failed and they are admitted to the Hospital.~Patients will not be followed up if admitted to any service. The study ends when final disposition is made.~Patients follow up after final disposition is not part of the study and will not be done." (NCT02057549)
Timeframe: at the time the decision for final disposition is made (about 8 hours)
| Intervention | hours (Median) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.8 |
| Conventional Therapy | 9 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 13 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 1.83 |
| Conventional Therapy | 3.39 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.53 |
| Conventional Therapy | 4.11 |
(NCT02057549)
Timeframe: 2 hours after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4 |
| Conventional Therapy | 13 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 5 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 3.13 |
| Conventional Therapy | 7.17 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 8.50 |
| Conventional Therapy | 8.28 |
1 trial available for haloperidol and Abdominal Pain
| Article | Year |
|---|---|
Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis.
Topics: Abdominal Pain; Adult; Analgesics; Antiemetics; Double-Blind Method; Drug Therapy, Combination; Fema | 2017 |
5 other studies available for haloperidol and Abdominal Pain
| Article | Year |
|---|---|
Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain.
Topics: Abdominal Pain; Adult; Antiemetics; Diabetes Mellitus; Emergency Service, Hospital; Female; Florida; | 2021 |
Study of Haloperidol for Abdominal Pain in the Emergency Department (SHAPE).
Topics: Abdominal Pain; Adolescent; Adult; Analgesics, Opioid; Antiemetics; Cross-Over Studies; Emergency Se | 2021 |
Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department.
Topics: Abdominal Pain; Adult; Antiemetics; California; Diabetes Mellitus, Type 1; Emergency Service, Hospit | 2017 |
Does administration of haloperidol or ketorolac decrease opioid administration for abdominal pain patients? A retrospective study.
Topics: Abdominal Pain; Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Ag | 2020 |
Haloperidol for treatment of cannabinoid hyperemesis syndrome.
Topics: Abdominal Pain; Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea | 2013 |